Total Payments
$424,974
2024 Payments
$6,048
Companies
10
Transactions
539
Payment Breakdown by Category
Other$273,178 (64.3%)
Consulting$102,515 (24.1%)
Travel$35,883 (8.4%)
Food & Beverage$11,848 (2.8%)
Research$1,513 (0.4%)
Education$36.63 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $272,428 | 119 | 64.1% |
| Consulting Fee | $102,515 | 29 | 24.1% |
| Travel and Lodging | $35,883 | 164 | 8.4% |
| Food and Beverage | $11,848 | 209 | 2.8% |
| Unspecified | $1,513 | 14 | 0.4% |
| Honoraria | $750.00 | 1 | 0.2% |
| Education | $36.63 | 3 | 0.0% |
Payments by Type
General
$423,460
525 transactions
Research
$1,513
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $179,720 | 178 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $85,444 | 124 | $0 (2021) |
| Gilead Sciences, Inc. | $84,893 | 164 | $0 (2020) |
| Napo Pharmaceuticals Inc | $45,254 | 18 | $0 (2024) |
| Janssen Products, LP | $27,839 | 36 | $0 (2019) |
| Theratechnologies Inc. | $883.98 | 4 | $0 (2019) |
| GlaxoSmithKline, LLC. | $749.36 | 6 | $0 (2018) |
| EMD Serono, Inc. | $85.18 | 1 | $0 (2017) |
| Janssen Scientific Affairs, LLC | $54.87 | 2 | $0 (2019) |
| Janssen Biotech, Inc. | $50.05 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,048 | 3 | Napo Pharmaceuticals Inc ($6,000) |
| 2023 | $24,313 | 12 | ViiV Healthcare Company ($12,313) |
| 2022 | $32,760 | 22 | ViiV Healthcare Company ($18,435) |
| 2021 | $52,636 | 28 | ViiV Healthcare Company ($35,516) |
| 2020 | $46,188 | 49 | ViiV Healthcare Company ($28,744) |
| 2019 | $146,475 | 223 | ViiV Healthcare Company ($57,285) |
| 2018 | $82,760 | 131 | Merck Sharp & Dohme Corporation ($26,591) |
| 2017 | $33,793 | 71 | Gilead Sciences Inc ($18,246) |
All Payment Transactions
539 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 04/09/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $48.22 | General |
| 01/10/2024 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 10/04/2023 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 09/29/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $39.12 | General |
| 09/18/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 09/08/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 06/28/2023 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 06/23/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Travel and Lodging | Cash or cash equivalent | $272.21 | General |
| Category: HIV | ||||||
| 06/23/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Travel and Lodging | Cash or cash equivalent | $235.88 | General |
| Category: HIV | ||||||
| 06/23/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | Cash or cash equivalent | $65.99 | General |
| Category: HIV | ||||||
| 06/02/2023 | ViiV Healthcare Company | RUKOBIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,550.00 | General |
| Category: HIV | ||||||
| 05/02/2023 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 04/04/2023 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 01/03/2023 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 10/03/2022 | Napo Pharmaceuticals Inc | Mytesi (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Infectious Disease | ||||||
| 09/30/2022 | ViiV Healthcare Company | RUKOBIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,150.00 | General |
| Category: HIV | ||||||
| 09/20/2022 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 08/27/2022 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $223.25 | General |
| 08/26/2022 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $80.20 | General |
| 08/26/2022 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $58.08 | General |
| 08/26/2022 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $39.82 | General |
| 08/26/2022 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $38.72 | General |
| 08/26/2022 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $35.95 | General |
| 08/26/2022 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: HIV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,411 | 11 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
About Dr. David Asmuth, M.D
Dr. David Asmuth, M.D is a Infectious Disease healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972573046.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Asmuth, M.D has received a total of $424,974 in payments from pharmaceutical and medical device companies, with $6,048 received in 2024. These payments were reported across 539 transactions from 10 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($272,428).
Ad
Practice Information
- Specialty Infectious Disease
- Location Sacramento, CA
- Active Since 01/23/2006
- Last Updated 01/27/2017
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1972573046
Products in Payments
- DOVATO (Drug) $61,160
- Mytesi (Drug) $45,254
- RUKOBIA (Drug) $41,247
- DELSTRIGO (Drug) $34,354
- ISENTRESS (Drug) $33,867
- Biktarvy (Drug) $19,289
- PREZCOBIX (Drug) $11,571
- Symtuza (Drug) $10,594
- TIVICAY (Drug) $10,580
- Descovy (Drug) $9,767
- Genvoya (Drug) $9,538
- Truvada (Drug) $9,420
- PIFELTRO (Drug) $6,007
- ZEPATIER (Drug) $5,534
- JULUCA (Drug) $3,400
- MK-8591 (Drug) $1,574
- MK-8591A (Drug) $896.27
- TROGARZO (Drug) $849.09
- SEROSTIM (Biological) $85.18
- EGRIFTA (Drug) $34.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Sacramento
Claire Pomeroy, M.d., M.b.a, M.D., M.B.A
Infectious Disease — Payments: $2.5M
Infectious Disease $2.5M
Stuart Cohen, M.d, M.D
Infectious Disease — Payments: $15,711
Infectious Disease $15,711
Daniel Ikeda, M.d, M.D
Infectious Disease — Payments: $8,220
Infectious Disease $8,220
Dr. Richard Pollard, Md, MD
Infectious Disease — Payments: $4,763
Infectious Disease $4,763
Vinod Trivedi, Md, MD
Infectious Disease — Payments: $4,508
Infectious Disease $4,508
Dr. Brett Laurence, Md, MD
Infectious Disease — Payments: $3,565
Infectious Disease $3,565